Q-omics provides the consensus-scored BOLA2-SMG1P6 profile across patient tissues and cancer cell-line models. BOLA2-SMG1P6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BOLA2-SMG1P6 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, BOLA2-SMG1P6 RNA expression shows 19,317 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where BOLA2-SMG1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BOLA2-SMG1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BOLA2-SMG1P6 survival associations across molecular data types. BOLA2-SMG1P6 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BOLA2-SMG1P6 RNA expression–survival associations across cancer types. High BOLA2-SMG1P6 expression shows unfavorable associations in ACC, KIRP, BLCA, UVM, LIHC and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BOLA2-SMG1P6 RNA expression.
This table summarizes BOLA2-SMG1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BOLA2-SMG1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BOLA2-SMG1P6 shows higher tumor expression in HNSC, LIHC, LUSC, BLCA, LUAD and KIRP. The HNSC box plot shows higher BOLA2-SMG1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.913, t-test p < 0.001).
This table shows molecular features associated with BOLA2-SMG1P6 in patient tissues and cancer cell lines. In patient samples, BOLA2-SMG1P6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
